Last edition
News about "Mantle Cell Lymphoma"
BeOne Medicines Reports Positive Phase 3 Results for Brukinsa in First-Line Mantle Cell Lymphoma
BeOne Medicines has reported positive Phase 3 results from the MANGROVE trial, showing that Brukinsa combined with rituximab significantly improves progression-free survival in previously untreated mantle cell lymphoma.
Mantle Cell Lymphoma | 02/07/2026 | By News Bureau
FDA Grants Accelerated Approval to BeOne Medicines' Beqalzi for Relapsed Mantle Cell Lymphoma
BeOne Medicines has secured accelerated US FDA approval for Beqalzi (sonrotoclax) to treat relapsed or refractory mantle cell lymphoma, marking an advancement in targeted therapies for patients with limited treatment options.
Mantle Cell Lymphoma | 16/05/2026 | By News Bureau | 105
FDA Grants Orphan Drug Designation to LP-284 of Lantern Pharma
The designation marks the third FDA orphan status for LP-284 and the sixth across Lantern Pharma’s AI-driven oncology pipeline, strengthening the programme’s development momentum in soft tissue sarcomas, a rare cancer segment with significant unmet need and a growing global market.
Mantle Cell Lymphoma | 21/01/2026 | By News Bureau | 181
Amneal Launches BORUZU for Multiple Myeloma and Mantle Cell Lymphoma
BORUZU™ (bortezomib injection), a proteasome inhibitor, is used for the treatment of multiple myeloma and mantle cell lymphoma.
Mantle Cell Lymphoma | 07/04/2025 | By Aishwarya | 311
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy